

09/868779

BOX PCT
PATENT
3813-0101P

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT: Keisuke TESHIGAWARA et al.
INTERNATIONAL APPL. NO.: PCT/JP00/07385 filed 10/23/2000
APPL. NO.: 09/868,779
Conf.:
FILED: June 21, 2001
FOR: METHOD FOR IN VITRO CULTURE OF
LYMPHOCYTES AND COMPOSITION
FOR USE OF IMMUNE THERAPY

LETTER SUBMITTING ADDITIONAL DOCUMENTS FOR
ENTERING NATIONAL PHASE FOR A PCT APPLICATION

BOX PCT

Assistant Commissioner for Patents
Washington, DC 20231

August 20, 2001

Sir:

Under the provisions of 37 C.F.R. § 1.494 or 37 C.F.R. § 1.495, attached hereto are the following additional items necessary for entering the national phase in connection with the above-identified PCT international application.

- ☒ Executed Declaration and Power of Attorney.
- ☒ Original ☐ Photocopy
- ☐ The specification attached to the executed Declaration and Power of Attorney is a true copy of the specification which was filed in the U.S. Patent and Trademark Office on June 21, 2001, including any amendments thereto (if applicable) filed on even date therewith.

☒ The undersigned hereby declares that "Attorney Docket No. 3813-0101P" on page 1 of the attached inventors' Declaration corresponds to Appl. No. 09/868,779 filed June 21, 2001 entitled "METHOD FOR IN VITRO CULTURE OF LYMPHOCYTES AND COMPOSITION FOR USE OF IMMUNE THERAPY."

☐ English language specification, claims, and Abstract with () sheets of drawings.

☐ Applicant claims small entity status under 37 C.F.R. § 1.27.

☒ Attached is a copy of Form PCT/DO/EO/905.

☐ _____

☐ No extension fee is required because the undersigned has not yet received the Notification of Missing Requirements (Form PCT/DO/EO/905). However, if for some reason it is determined that an extension of time is necessary, applicant hereby respectfully petitions for an extension of time for the filing of the present paper in accordance with the provisions of 37 C.F.R. § 1.136 and 37 C.F.R. § 1.17.

☐ Applicant(s) hereby respectfully petitions for () month(s) extension of time for the filing of the present paper in accordance with the provisions of 37 C.F.R. § 1.136 and 37 C.F.R. § 1.17. The required fee of \$0.00 is attached hereto.

The Government Filing Surcharge in the amount of \$130.00 in accordance with 37 C.F.R. §§ 1.494 and 1.492 was previously paid for concurrently with the filing of the application on June 21, 2001.


- ☐ Submitted concurrently herewith **under separate cover** for recording is an Assignment.
- ☐ A check in the amount of \$0.00 to cover the above-mentioned fees is enclosed.
- ☐ A Fee of \$0.00 to cover the increase in fees of the filing Surcharge is enclosed.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By


Raymond C. Stewart, #21,066

RCS/bsh
3813-0101P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachments

Rev. 1-1-1



Dep. of Reg. RM 307

PATENT
3813-0101P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Keisuke TESHIGAWARA et al.
Appl. No.: 09/868,779 Group: Unassigned
Filed: June 21, 2001 Examiner: Unassigned
For: METHOD FOR IN VITRO CULTURE OF
LYMPHOCYTES AND COMPOSITION FOR USE OF
IMMUNE THERAPY
ATTENTION: Refund Section
Accounting Division
OFFICE OF FINANCE

FEE VALUE ACCOUNTABILITY	
DEPOSIT ACCOUNT NO.	
02	2448
910 960 ²⁰	
154 13	
968 20	
911 754	
254 65	
969	135

REQUEST FOR A REFUND OF 50% OF THE FILING FEE

Assistant Commissioner for Patents
Washington, DC 20231

August 20, 2001

Sir:

The following documentation and remarks are respectfully
submitted in connection with the above-identified application.

DOCUMENTATION

Attached hereto is:

- ☒ a copy of written assertion of small entity status
filed on even date herewith under separate cover; and/or
- ☐ a copy of an executed Statement Claiming Small Entity
Status (37 C.F.R. § 1.9(f) and 1.27()) - filed on even
date herewith under separate cover.

REMARKS

Pursuant to 37 C.F.R. § 1.28(a), applicants hereby request a
refund of 50% of the Filing Fee. Small entity status has been

established by the filing of a written assertion/statement on August 20, 2001.

Small entity applicants may now file the necessary Statement within three (3) months of the date of payment of any particular fee and request a refund. The present application qualifies for the reduced fees as implemented by the U.S. Patent and Trademark Office on October 1, 1982, and further amended on January 20, 1983 and September 8, 2000.


The present application was filed on June 21, 2001 with a filing fee of \$1,260.00. It is respectfully requested that the excess fee of \$630.00 be credited to Deposit Account No. 02-2448.

Favorable action on the present Request is respectfully requested.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIFCH, LLP

By  #3288
to Raymond C. Stewart, #21,066

FCS/bsh
3813-0101P
Attachments

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000



PATENT
3813-0101P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Keisuke TESHIGAWARA et al.
Appl. No.: 09/868,779 Group: Unassigned
Filed: June 11, 2001 Examiner: Unassigned
For: METHOD FOR IN VITRO CULTURE OF LYMPHOCYTES
AND COMPOSITION FOR USE OF IMMUNE THERAPY

ASSERTION OF SMALL ENTITY STATUS

Assistant Commissioner for Patents
Washington, DC 20231

August 20, 2001

Sir:


The above-identified application qualifies for small entity status. This written assertion of small entity status should satisfy the requirements of 37 C.F.R. § 1.27.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2443 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By

 #32,881
Raymond C. Stewart, #21,066

RCS/bsh
3813-0101P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000



UNITED STATES PATENT &

TRADEMARK OFFICE

Commissioner for Patents, Box 10
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/868779	TESHIGAWARA	K 3813-0101P
BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040 0747		INTERNATIONAL APPLICATION NO. PCT/JP00/07385
Docketed 9-30-01		FILED DATE 23 OCT 00
		PRIORITY DATE 21 OCT 99

DATE MAILED

31 JUL 2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☒ a Designated Office (37 CFR 1.494) ☐ an Elected Office (37 CFR 1.495):
- | | |
|---|--|
| <input checked="" type="checkbox"/> U.S. Basic National Fee. | <input type="checkbox"/> Indication of Small Entity Status. |
| <input checked="" type="checkbox"/> Copy of the international application. | <input checked="" type="checkbox"/> Translation of the international application into English. |
| <input type="checkbox"/> Oath or Declaration of inventor(s). | <input type="checkbox"/> Translation of Article 19 amendments into English. |
| <input type="checkbox"/> Copy of Article 19 amendments. | <input type="checkbox"/> Other: |
| <input type="checkbox"/> Priority Document. | |
| <input type="checkbox"/> The International Preliminary Examination Report in English and its Annexes, if any. | |
| <input type="checkbox"/> Translation of Annexes to the International Preliminary Examination Report into English. | |
2. ☒ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.
- | | |
|--|--|
| <input type="checkbox"/> U.S. Basic National Fee | <input type="checkbox"/> Copy of the international application |
|--|--|
3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:
- | | |
|--|--|
| <input type="checkbox"/> a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date. | |
| <input type="checkbox"/> The current translation is defective for the reasons indicated on the attached Notice of Defective Translation. | |
| <input type="checkbox"/> b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)). | |
| <input checked="" type="checkbox"/> c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date. | |
| <input type="checkbox"/> The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917. | |
| <input type="checkbox"/> d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)). | |
4. Additional claim fees of \$_____ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.
5. ☐ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

Enclosed: ☐ PCT/DO/EO 917 ☐ Notice of Defective Translation
☐ PTO-875 ☐ PCT/DO/EO-920

Winston M. Alvarado

Telephone: 703-305-6421